Clinical Trial Update: A 28-Week Open Label Extension Study Evaluating Safety and Tolerability of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment [Phase 4]

View source ↗

Summary

A 28-week open-label extension study evaluating the safety and tolerability of donepezil hydrochloride in subjects with mild cognitive impairment (Phase 4).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Impairment

Drugs mentioned

• Aricept (Donepezil)

Snippet

Sponsor: Eisai Inc. | Conditions: Mild Cognitive Impairment | Phase 4 | Status: COMPLETED | Results posted: 2009-07-08